Vimta Labs Limited (VIMTALABS.NS)
INR 1016.0
(2.42%)
INR 1016.0
(2.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 878.1 Million INR | -11.55% |
| 2022 | 957.58 Million INR | 13.48% |
| 2021 | 802.73 Million INR | 47.76% |
| 2020 | 537.41 Million INR | 80.25% |
| 2019 | 303.85 Million INR | -50.27% |
| 2018 | 581.04 Million INR | 34.22% |
| 2017 | 458 Million INR | 72.79% |
| 2016 | 278.02 Million INR | 38.64% |
| 2015 | 189.19 Million INR | -0.34% |
| 2014 | 174.13 Million INR | -26.66% |
| 2013 | 261.46 Million INR | 14.67% |
| 2012 | 217.31 Million INR | 393.12% |
| 2011 | 22.05 Million INR | -70.14% |
| 2010 | 144.6 Million INR | -18.97% |
| 2009 | 209.94 Million INR | -14.56% |
| 2008 | 239.21 Million INR | -6.82% |
| 2007 | 255.92 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 245.21 Million INR | -1.55% |
| 2023 Q1 | 246.5 Million INR | -0.78% |
| 2023 Q2 | 179.2 Million INR | -27.3% |
| 2023 Q4 | 244.18 Million INR | 7.41% |
| 2023 Q3 | 227.34 Million INR | 26.86% |
| 2023 FY | - INR | -11.55% |
| 2022 Q3 | 225.79 Million INR | -13.61% |
| 2022 Q4 | 248.43 Million INR | 10.03% |
| 2022 FY | - INR | 13.48% |
| 2022 Q1 | 247.98 Million INR | -12.75% |
| 2022 Q2 | 261.35 Million INR | 5.39% |
| 2021 FY | - INR | 47.76% |
| 2021 Q1 | 168.72 Million INR | -22.59% |
| 2021 Q2 | 200.69 Million INR | 18.95% |
| 2021 Q4 | 284.23 Million INR | 33.38% |
| 2021 Q3 | 213.09 Million INR | 6.18% |
| 2020 Q4 | 217.96 Million INR | 28.37% |
| 2020 Q2 | 160.27 Million INR | 315.64% |
| 2020 Q1 | 38.56 Million INR | -26.54% |
| 2020 FY | - INR | 80.25% |
| 2020 Q3 | 169.79 Million INR | 5.94% |
| 2019 Q2 | 66.57 Million INR | -10.28% |
| 2019 Q4 | 52.49 Million INR | -57.42% |
| 2019 FY | - INR | -50.27% |
| 2019 Q1 | 74.2 Million INR | -62.97% |
| 2019 Q3 | 123.27 Million INR | 85.17% |
| 2018 Q4 | 200.38 Million INR | 47.53% |
| 2018 FY | - INR | 34.22% |
| 2018 Q3 | 135.82 Million INR | -19.64% |
| 2018 Q2 | 169.02 Million INR | 13.27% |
| 2018 Q1 | 149.22 Million INR | 9.18% |
| 2017 Q1 | 62.84 Million INR | -8.27% |
| 2017 Q4 | 136.67 Million INR | -3.5% |
| 2017 FY | - INR | 72.79% |
| 2017 Q3 | 141.62 Million INR | 14.69% |
| 2017 Q2 | 123.49 Million INR | 96.5% |
| 2016 Q2 | 61.14 Million INR | -14.66% |
| 2016 Q1 | 71.65 Million INR | 93.68% |
| 2016 Q4 | 68.51 Million INR | -8.65% |
| 2016 FY | - INR | 38.64% |
| 2016 Q3 | 74.99 Million INR | 22.65% |
| 2015 FY | - INR | -0.34% |
| 2015 Q4 | 36.99 Million INR | -25.47% |
| 2015 Q2 | 72.65 Million INR | 64.16% |
| 2015 Q3 | 49.64 Million INR | -31.67% |
| 2015 Q1 | 44.25 Million INR | -29.44% |
| 2014 Q3 | 36.25 Million INR | -20.71% |
| 2014 Q4 | 62.72 Million INR | 72.98% |
| 2014 Q2 | 45.72 Million INR | -23.2% |
| 2014 FY | - INR | -26.66% |
| 2014 Q1 | 59.53 Million INR | 82.87% |
| 2013 Q2 | 86.63 Million INR | 7.29% |
| 2013 Q4 | 32.55 Million INR | -58.56% |
| 2013 FY | - INR | 14.67% |
| 2013 Q3 | 78.55 Million INR | -9.32% |
| 2013 Q1 | 80.74 Million INR | -3.08% |
| 2012 Q4 | 83.31 Million INR | 55.48% |
| 2012 FY | - INR | 393.12% |
| 2012 Q1 | 55.49 Million INR | 6178.59% |
| 2012 Q3 | 53.58 Million INR | 6.17% |
| 2012 Q2 | 50.47 Million INR | -9.04% |
| 2011 FY | - INR | -70.14% |
| 2011 Q4 | -912.89 Thousand INR | -111.1% |
| 2011 Q3 | 8.22 Million INR | -54.07% |
| 2011 Q2 | 17.9 Million INR | 0.0% |
| 2010 FY | - INR | -18.97% |
| 2009 FY | - INR | -14.56% |
| 2008 FY | - INR | -6.82% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Krsnaa Diagnostics Limited | 1.61 Billion INR | 45.474% |
| Dr. Lal PathLabs Limited | 6.78 Billion INR | 87.051% |
| Metropolis Healthcare Limited | 2.96 Billion INR | 70.434% |
| Thyrocare Technologies Limited | 1.48 Billion INR | 40.721% |
| Vijaya Diagnostic Centre Limited | 2.2 Billion INR | 60.249% |